Sonoma Pharmaceuticals files prospectus supplement for existing at-the-market equity offering

Sonoma Pharmaceuticals, Inc.

Company entered into Equity Distribution Agreement with Maxim Group LLC on Dec 15, 2023, amended March 8, 2024.
Prospectus supplement filed Aug 23, 2024 for sales of common stock under effective S-3 registration statement.
Shares may be offered and sold through Maxim as sales agent or principal, at-the-market.
Legal opinion of Polsinelli PC regarding share validity filed as Exhibit 5.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.